T3D Therapeutics

Overview

T3D Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead program, T3D-959, is a first-in-class PPAR delta/gamma dual agonist that targets metabolic dysfunction in the brain, a key underlying contributor to Alzheimer's disease pathology["@therapeutics"].

Overview

T3D Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead program, T3D-959, is a first-in-class PPAR delta/gamma dual agonist that targets metabolic dysfunction in the brain, a key underlying contributor to Alzheimer's disease pathology["@therapeutics"].

Founded in 2013 and headquartered in Research Triangle Park, North Carolina, T3D Therapeutics takes a metabolic approach to treating Alzheimer's disease, targeting the brain's energy metabolism and insulin signaling pathways that become impaired in neurodegeneration.

Pipeline Overview

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| T3D-959 | PPAR δ/γ dual agonist | Alzheimer's disease | Phase 2 | Active |
| T3D-231 | PPAR δ selective agonist | Parkinson's disease | Phase 1 | Completed |
| T3D-102 | Neuroinflammation modulator | Alzheimer's disease | Preclinical | Research |

Lead Program: T3D-959

Mechanism of Action

T3D-959 is a first-in-class small molecule that activates both PPAR delta and PPAR gamma receptors, addressing metabolic dysfunction in the brain:

Metabolic Benefits:

• Improves brain glucose uptake and utilization
• Enhances mitochondrial function
• Reduces neuroinflammation
• Protects neuronal function
• Improves insulin sensitivity in the brain

• Oral bioavailability
• Brain penetrant
• Dual PPAR δ/γ activation
• Good safety profile in clinical trials

Clinical Development

Phase 1 Studies:

Completed Phase 1 studies demonstrating:

• Safety and tolerability in healthy volunteers
• Target engagement in the brain
• Dose-proportional pharmacokinetics
• No significant weight gain (different from single PPAR gamma agonists)

The Phase 2 PIONEER study in patients with mild-to-moderate Alzheimer's disease is evaluating:

• Cognitive outcomes (ADAS-Cog11, MMSE)
• Biomarker endpoints (glucose metabolism, inflammation markers)
• Safety and tolerability
• Functional outcomes

Science and Research

Metabolic Dysfunction in Alzheimer's Disease

T3D Therapeutics targets brain metabolic dysfunction, which is increasingly recognized as a key contributor to Alzheimer's disease:

Key Findings:

• Brain glucose metabolism declines early in AD
• Insulin signaling is impaired in AD brains
• [Mitochondrial](/mechanisms/mitochondrial-dysfunction) function is compromised
• Metabolic deficits correlate with cognitive decline
• PPAR agonists can improve brain energy metabolism

PPAR Receptor Biology

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate metabolism:

PPAR Delta:

• Regulates fatty acid oxidation
• Improves mitochondrial function
• Enhances neuronal survival
• Modulates inflammation

• Improves insulin sensitivity
• Reduces inflammation
• Regulates lipid metabolism
• May improve amyloid clearance

Why Dual Agonism?

T3D-959's dual mechanism provides benefits:

• Combined metabolic improvement
• Enhanced neuroprotection
• Reduced inflammation
• Better safety profile than single agonists

Corporate Information

Headquarters: Research Triangle Park, North Carolina, USA

Founded: 2013

Funding:

• Series A: $15 million (2014)
• Series B: $30 million (2017)
• Strategic partnership: $50 million (2020)

• Dr. John C. K. - CEO and Co-founder
• Dr. Maciej J. - CSO and Co-founder
• Dr. Lisa M. - CMO

Recent Developments (2024-2025)

• 2025: T3D-959 Phase 2 PIONEER trial enrolled first patients
• 2024: Positive Phase 1b results showing cognitive improvement signals
• 2024: Received Fast Track designation from FDA
• 2023: Completed Phase 1b study in mild cognitive impairment

Competitive Landscape

| Company | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Phase 2 |
| Eli Lilly | [Donanemab](/entities/donanemab) | Anti-amyloid | Approved |
| Biogen/Eisai | [Lecanemab](/entities/lecanemab) | Anti-amyloid | Approved |
| Cognition/Novartis | CT1812 | Sigma-2 antagonist | Phase 2 |
| Lyterian | LYT-100 | [NLRP3](/entities/nlrp3-inflammasome) inhibitor | Phase 1b/2a |

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Metabolic Dysfunction in AD](/mechanisms/brain-metabolic-dysfunction)
• [PPAR Signaling](/mechanisms/ppar-signaling-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References